{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T22:45:24Z","timestamp":1759099524659},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1300,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1111\/j.1742-1241.2012.02893.x","type":"journal-article","created":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T23:49:38Z","timestamp":1328831378000},"page":"251-261","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry"],"prefix":"10.1155","volume":"66","author":[{"given":"U.","family":"Zeymer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dechend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Senges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the 3A Registry Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,9]]},"reference":[{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1001\/jama.289.18.2363","article-title":"Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States","volume":"289","author":"Wolf-Maier","year":"2003","journal-title":"J Am Med Ass"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00004872-200403000-00009","article-title":"High prevalence and poor control of hypertension in primary care: cross sectional study","volume":"22","author":"Sharma","year":"2004","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1055\/s-2006-956253","article-title":"Epidemiologie der arteriellen Hypertonie in Deutschland. Ausgew\u00e4hlte Ergebnisse bev\u00f6lkerungsrepr\u00e4sentativer Querschnittstudien","volume":"131","author":"L\u00f6wel","year":"2006","journal-title":"Dtsch Med Wochenschr"},{"volume-title":"DETECT. Ergebnisse einer klinisch-epidemiologischen Querschnitts- und Verlaufsstudie mit 50.000 Patienten in 3.000 Hausarztpraxen","year":"2007","author":"Pittrow","key":"10.1111\/j.1742-1241.2012.02893.x-BIB4|cit4"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0271-2","article-title":"Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists","volume":"100","author":"Thoenes","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias","volume":"335","author":"MacMahon","year":"1990","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Blood Pressure Lowering Treatment Trialists Collaboration","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.107.724104","article-title":"When more is not better: treatment intensification among hypertensive patients with poor medication adherence","volume":"117","author":"Heisler","year":"2008","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.01201005","article-title":"Direct renin inhibition with aliskiren in hypertension and target organ damage","volume":"1","author":"Muller","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker","volume":"49","author":"O\u2019Brien","year":"2007","journal-title":"Hypertension"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.amjcard.2010.04.040","article-title":"Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease","volume":"106","author":"Muhlestein","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB12|cit12","unstructured":"Muhlestein JB May HT Bair TL et\u00a0al. Elevated plasma renin activity (PRA) is associated with adverse renal outcomes in patients with coronary artery disease (SU 089)"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2165\/11204360-000000000-00000","article-title":"Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension","volume":"70","author":"Duggan","year":"2010","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/jhh.2009.38","article-title":"Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study","volume":"24","author":"Palatini","year":"2010","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB16|cit16","unstructured":"D\u00fcsing R Baschiera F Baek I Brunel P Aliskiren provides more prolonged reductions in 24-hour mean ambulatory blood pressure during treatment withdrawal than telmisartan [Poster 15.393] http:\/\/journals.lww.com\/jhypertension\/Documents\/ESH%202011%20Poster%20Sessions.pdf"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/17425255.2011.538681","article-title":"Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment","volume":"7","author":"Reboldi","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/VHRM.S8175","article-title":"Aliskiren and valsartan combination therapy for the management of hypertension","volume":"6","author":"Epstein","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB19|cit19","doi-asserted-by":"crossref","unstructured":"de Cotret P Steele A Leclerc JM et\u00a0al. Real-life blood pressure reductions in hypertension patients treated with aliskiren. Interim results of the Canadian Anchor registry (4A.05) J Hypertens 2011 29","DOI":"10.1097\/00004872-201106001-00121"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB20|cit20","unstructured":"Steele A de Cotret PR Hubert M et\u00a0al. EDTA: Effects of an aliskiren-based treatment on blood pressure and urinary albumin creatinine ratio in hypertensive outpatients: results of an interim analysis of the Canadian ANCHOR registry"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB21|cit21","doi-asserted-by":"crossref","unstructured":"Volpe M Tocci G Bianchini F et\u00a0al. Use of aliskiren in a \u2018real-life\u2019 model of hypertension management: analysis of national Web-based drug-monitoring system in Italy J Hypertens 2012 30 194 203","DOI":"10.1097\/HJH.0b013e328351bf9c"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB22|cit22","unstructured":"European Medicines Agency (EMA) http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000780\/WC500047010.pdf"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/08037050903450468","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"18","author":"Mancia","year":"2009","journal-title":"Blood Press"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB24|cit24","unstructured":"Deutsche Hypertonie Gesellschaft - Deutsche Hochdruckliga e.V. (DHL) http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/046-001_S2_Behandlung_der_arteriellen_Hypertonie_06-2008_06-2013.pdf"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB25|cit25","unstructured":"National Institute for Clinical Excellence (NICE) http:\/\/www.nice.org.uk\/nicemedia\/live\/13561\/56007\/56007.pdf"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB26|cit26","unstructured":"Bundesministerium f\u00fcr Gesundheit http:\/\/www.g-ba.de\/downloads\/39-261-1046\/2009-12-17-AMR4-Aliskiren_BAnz.pdf"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB27|cit27","unstructured":"Verband der forschenden Arzneimittelhersteller (VfA) http:\/\/www.vfa.de\/de\/arzneimittel-forschung\/datenbanken-zu-arzneimitteln\/nisdb\/nis-details\/_616"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1742-1241.2010.02562.x","article-title":"Antihypertensive effectiveness of aliskiren for the \u2018real-world\u2019 management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study)","volume":"65","author":"Verpooten","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1370\/afm.272","article-title":"Prevalence of multimorbidity among adults seen in family practice","volume":"3","author":"Fortin","year":"2005","journal-title":"Ann Fam Med"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/08037050310030982","article-title":"HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients","volume":"13","author":"Steckelings","year":"2004","journal-title":"Blood Press"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1055\/s-2007-991668","article-title":"[Care of hypertensive patients seen by cardiologists: results of the Snapshot Hypertension Registry]","volume":"132","author":"Silber","year":"2007","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB34|cit34","first-page":"155","article-title":"[Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT)]","volume":"105","author":"Muller","year":"2010","journal-title":"Med Klin (Munich)"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/07853890.2010.543922","article-title":"Impact of new clinical trials on recent guidelines on hypertension management","volume":"43","author":"Mancia","year":"2011","journal-title":"Ann Med"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3810\/pgm.2011.01.2249","article-title":"Long-term blood pressure control: what can we do?","volume":"123","author":"Neutel","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB37|cit37","first-page":"1462","article-title":"2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1753944710369682","article-title":"Aliskiren versus ramipril in hypertension","volume":"4","author":"Verdecchia","year":"2010","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan","volume":"20","author":"Pool","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1185\/03007995.2010.528282","article-title":"Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension","volume":"26","author":"Chrysant","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2012.02893.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2012.02893.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2012.02893.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:58Z","timestamp":1643349958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2012.02893.x"}},"subtitle":["Aliskiren under real-life practice conditions"],"short-title":[],"issued":{"date-parts":[[2012,2,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2012.02893.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"type":"print","value":"1368-5031"}],"subject":[],"published":{"date-parts":[[2012,2,9]]}}}